Investigational Crohn's Disease Drug Shows Favorable Results in Clinical Trial

Specialty Pharmacy TimesNovember/December 2014
Volume 5
Issue 6

An experimental drug developed by Celgene exhibited strong efficacy and safety results during a recent phase 2 study.

Mongersen, an oral topically active Smad7 antisense oligonucleotide, demonstrated a statistically significant remission rate compared with placebo after 2 weeks of treatment.

The double-blind, placebo-controlled trial evaluated the efficacy of Mongersen as induction therapy in steroid-dependent or steroid-resistant patients with active Crohn’s disease (Crohn’s disease activity index [CDAI] score 220-400). Patients were randomized to Mongersen at doses of 10 mg, 40 mg, or 160 mg per day, or placebo, for 2 weeks.

A greater proportion of patients achieved statistically significant remission rates receiving Mongersen 40 mg per day (55%) and 160 mg per day (65.1%) compared with placebo (9.5%). There was not found to be a significant difference in clinical remission in the 10-mg per day group (12.2%) compared with the placebo group. The clinical response rate was also significantly greater among patients receiving Mongersen at doses of 10 mg per day (36.6%), 40 mg per day (57.5%), or 160 mg per day day (72.1%) compared with placebo (16.7%; P = .039, P = .0001 and P <.0001, respectively).

Adverse events and serious adverse events were similar across all treatment groups. There were 9 serious adverse events in 6 patients, mostly consisting of hospital admissions for complications or symptoms associated with Crohn’s disease.

The study did not report any toxicities previously found with systemically active antisense agents.

Related Videos
Practice Pearl #1 Active Surveillance vs Treatment in Patients with NETs
© 2024 MJH Life Sciences

All rights reserved.